Analysis Demonstrates No Increased Incidence of Thrombosis with TTS After Vaxzevria Second Dose

News
Article

A global safety database analysis has demonstrated no increased incidence of thrombosis with TTS after the second dose of Vaxzevria.

A global safety database analysis, recently published in The Lancet, has demonstrated that there is no increased incidence of thrombosis with thrombocytopenia syndrome (TTS) after the second dose of AstraZeneca and Oxford University’s COVID-19 vaccine, Vaxzevria. The results of the analysis were revealed in an AstraZeneca press release on July 28, 2021.

According to the analysis, which was performed using AstraZeneca’s global safety database, the estimated rate of TTS following the second dose of Vaxzevria was comparable to the background rate of TTS observed in an unvaccinated population. These results were in line with recent reports from the United Kingdom’s Medicines and Healthcare products Regulatory Agency Yellow Card Report.

Sir Mene Pangalos, executive vice-president, BioPharmaceuticals R&D, said, in the press release, “Vaxzevria is effective against all severities of COVID-19, and it plays a critical role in combatting the pandemic. Unless TTS was identified after the first dose, these results support the administration of the two-dose schedule of Vaxzevria, as indicated, to help provide protection against COVID-19 including against rising variants of concern.”

Source: AstraZeneca

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content